**Amendments to the Claims:**

This listing of claims will replace all prior versions and listings of claims in the application.

**Listing of Claims:**

1. (Currently Amended) A method for the selective enhancement of the expression of a Stra6 protein in a tumor cell ~~characterized by aberrant Wnt signaling~~ comprising treating said tumor cell with an effective amount of a retinoid to selectively enhance expression of a Stra6 protein having at least 95% sequence identity to a polypeptide comprising an amino acid sequence of SEQ ID NO:2, wherein the tumor cell is characterized by aberrant Wnt signaling.

2. (Canceled)

3. (Previously Presented) The method of claim 1, wherein said Stra6 protein is a cell surface protein.

4. (Previously Presented) The method of claim 1 wherein said Stra6 protein is over-expressed in tumor cells relative to normal cells of the same tissue type as the tumor cells.

5-7. (Canceled)

8. (Original) The method of claim 1 wherein said retinoid is a retinoic acid.

9. (Original) The method of claim 1 wherein said tumor is a human cancer.

10. (Previously presented) The method of claim 9 wherein said human cancer is colon cancer, or breast cancer.

11-66. (Cancelled)

67. (Currently Amended) A method for the selective enhancement of expression of a Stra6 protein in a tumor cell ~~characterized by aberrant Wnt signaling~~ comprising treating said tumor cell with an effective amount of a retinoid, ~~wherein said Stra6 protein is characterized by~~

~~synergistic enhancement of its~~ to synergistically enhance expression of a Stra 6 protein having at least 95% sequence identity to a polypeptide comprising an amino acid sequence of SEQ ID NO:2, ~~by a combination of Wnt-1 and said retinoid~~ wherein said tumor cell is characterized by expression of Wnt-1.

68. (Previously Presented) The method of claim 67, wherein said Stra6 protein is a cell surface protein.

69. (Previously Presented) The method of claim 67, wherein said Stra6 protein is overexpressed in tumor cells relative to normal cells of the same tissue type as the tumor cells.

70. (Canceled)

71. (Previously presented) The method of claim 67, wherein said retinoid is a retinoic acid.

72. (Previously presented) The method of claim 67, wherein said tumor is a human cancer.

73. (Previously presented) The method of claim 72, wherein said human cancer is colon cancer or breast cancer.

74. (Currently Amended) A method for selective enhancement of the expression of a Stra6 protein in a tumor cell ~~characterized by aberrant Wnt signaling of a member of Wnt signaling pathway selected from the group consisting of Wnt gene family, APC, catenin, frizzled receptors, dishevelled protein, glycogen synthase kinase 3$\beta$, transcription factor TCF/LEF-1, nodal related 3 gene, Xnr3, the homeobox genes, engrailed, goosecoid, twin (Xtwn), siamois, c-myc and the WISP genes~~, comprising treating said tumor cell with an effective amount of a retinoid to selectively enhance expression of a Stra6 protein having least 95% sequence identity to a polypeptide comprising SEQ ID NO:2, wherein the tumor cell is characterized by aberrant signaling of a member of the Wnt pathway selected from the group consisting of Wnt gene

family, APC, catenin, frizzled receptors, dishevelled protein, glycogen synthase kinase-3β, transcription factor TCF/LEF-1, nodal related 3 gene, Xnr3, the homeobox genes, engrailed, goosecoid, twin (Xtwn), siamois, c-myc and the WISP genes.

75. (Previously Presented) The method of claim 74, wherein the Stra6 protein is a cell surface protein.

76. (Previously Presented) The method of claim 74, wherein said Stra6 protein is overexpressed in tumor cells relative to normal cells of the same tissue type as the tumor cells.

77. (Canceled)

78. (Previously presented) The method of claim 74, wherein the retinoid is retinoic acid.

79. (Previously presented) The method of claim 74, wherein the tumor is human cancer.

80. (Previously presented) The method of claim 79, wherein the human cancer is colon cancer or breast cancer.

81. (New)The method of claim 74, wherein the member of the Wnt pathway is selected from the group consisting of the Wnt gene family, APC, catenin, dishevelled protein, glycogen synthase kinase-3β, transcription factor TCF/LEF-1, nodal related 3 gene, Xnr3, engrailed, goosecoid, twin (Xtwn), siamois, and c-myc.

82. (New)The method of claim 74, wherein the member of the Wnt pathway is selected from the group consisting of Wnt-1, β-catenin, WISP genes and APC.

83. (New) The method of claim 74, wherein the member of the Wnt pathway is Wnt-1.

84. (New) A method comprising:

a) identifying a tumor cell that is characterized by aberrant signaling of a member of the Wnt pathway; and

b) treating the tumor cell with an effective amount of a retinoid to selectively enhance expression of a Stra6 protein having at least 95% sequence identity to polypeptide comprising an amino acid sequence of SEQ ID NO:2.

85. (New) The method of claim 84, wherein the member of the Wnt pathway is selected from the group consisting of Wnt gene family, APC, catenin, frizzled receptors, dishevelled protein, glycogen synthase kinase-3$\beta$, transcription factor TCF/LEF-1, nodal related 3 gene, Xnr3, the homeobox genes, engrailed, goosecoid, twin (Xtwn), siamois, c-myc and the WISP genes.

86. (New) The method of claim 84, wherein the member of the Wnt pathway is selected from the group consisting of Wnt-1, $\beta$-catenin, WISP genes and APC.

87. (New) The method of claim 84, wherein the member of the Wnt pathway is Wnt-1.

88. (New) The method of claim 84, wherein said retinoid is retinoic acid.

89. (New) The method of claim 84, wherein the tumor cell is a human tumor cell.

90. (New) The method of claim 89, wherein the tumor cell is colon or breast cancer cell.